Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population

Journal of Gastroenterology

Volumn 39, Issue 10, 2004, Pages 927-930

  Shimoyama, Tadashi ^a   Fukuda, Shinsaku ^a   Mikami, Tatsuya ^a   Fukushi, Michio ^a   Munakata, Akihiro ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Clarithromycin resistance; Helicobacter pylori; Metronidazole

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG USE; ENDOSCOPY; FEMALE; FREQUENCY ANALYSIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; JAPAN; MALE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS;

EID: 8544280733     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-004-1424-8     Document Type: Article

References (21)

1. Satoh K. Indications for Helicobacter pylori eradication therapy and first-line therapy regimen in Japan: Recommendation by the Japanese Society for Helicobacter Research. J Gastroenterol 2002;37(suppl 13):34-8.
2. Miwa H, Misawa H, Yamada T, Nagahara A, Ohtaka K, Sato N. Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: A multiple logistic regression analysis. Dig Dis Sci 2001;46:2445-50.
3. Hoshiya S, Watanabe K, Tokunaga K, Tanaka A, Ninomiya H, Shingaki M, et al. Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. J Gastroenterol 2000;35:10-4.
4. Hua JS, Bow H, Zheng PY, Khay-Guan Y. Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in Singapore. World J Gastroenterol 2000;6:119-21.
5. Yakoob J, Fan X, Hu G, Liu L, Zhang Z. Antibiotic susceptibility of Helicobacter pylori in the Chinese population. J Gastroenterol Hepatol 2001;16:981-5.
6. Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 2003;17:119-23.
7. Kato M, Yamaoka Y, Kim JJ, Reddy R, Asaka M, Kashima K, et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000;44:2214-6.
8. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin: Influence to treatment outcome. Am J Gastroenterol 1998;93:386-9.
9. Poon SK, Chang CS, Su J, Lai CH, Yang CC, Chen GH, et al. Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. Aliment Pharmacol Ther 2002;16:291-6.
10. Perez Aldana L, Kato M, Nakagawa S, Kawarasaki M, Nagasako T, Mizushima T, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002;7:306-9.
11. Umegaki N, Shimoyama T, Nishiya D, Suto T, Fukuda S, Munakata A. Clarithromycin resistant and point mutation in the 23S rRNA gene in Helicobacter pylori isolates from Japan. J Gastroenterol Hepatol 2000;15:906-9.
12. Versalovic J, Shortridge D, Kibler K, Griffy MV, Beyer J, Flamm RK, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996;40:477-80.
13. Nagahara A, Miwa H, Ohkura R, Yamada T, Sato K, Hojo M, et al. Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2001;16: 613-8.
14. Prazeres Magalhaes P, De Magalhaes Queiroz DM, Campos Barbosa DV, Aguiar Rocha G, Nogueira Mendes E, Santos A, et al. Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. Antimicrob Agents Chemother 2002;46:2021-3.
15. Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998;115:1278-82.
16. Miyaji H, Azuma T, Ito S, Suto H, Ito Y, Yamazaki Y, et al. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. Aliment Pharmacol Ther 1997;11:1131-6.
17. Kawano S, Murakami M, Saita H, Tsuji S. Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication. J Gastroenterol 1996;31(suppl 9):41-3.
18. Ishizaki T, Horai Y. Cytochrome P450 and the metabolism of proton pump inhibitors: Emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13(suppl 3):27-36.
19. Goddard AF, Jessa MJ, Barrett DA, Shaw PN, Idstrom JP, Cederberg C, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996;111:358-67.
20. Sherwood PV, Wibawa JI, Atherton JC, Jordan N, Jenkins D, Barrett DA, et al. Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibiotics in rats. Gut 2002;51:490-5.
21. Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dahlin DC. Cancer after exposure to metronidazole. Mayo Clin Proc 1988;63:147-53.